Board of Directors
The Company’s Board of Directors is comprised of seven members.

Alan Dunton, M.D.

Alan W. Dunton, M.D., has served as a member of our Board of Directors since 2011. Dr. Dunton has over 25 years of experience as an executive in the pharmaceutical/biotechnology industry. His career has ranged from responsibility for overall leadership of large pharmaceutical research & development organizations to private biotechnology companies focused on prescription (Rx) and over-the-counter (OTC) drug development, as well as devices. Dr. Dunton is the founder and principal of Danerius, LLC, a consulting firm that works with small to mid-size pharmaceutical companies to guide them through drug development programs and regulatory issues, assist them in identifying and evaluating product opportunities, and secure funding or partnering opportunities. He has held several senior positions in major pharmaceutical companies. Most recently, he served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc., a company focused on treatment resistant HIV therapeutics. Previously, he was the President and CEO of Metaphore Pharmaceuticals, which focused on anti-inflammatory and analgesic products. Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including President and Managing Director of The Janssen Research Foundation. He also served as Group Vice President of Global Clinical Research & Development of Janssen, as well as the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Dr. Dunton has also held positions in clinical research & development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc. Dr. Dunton serves on several Boards of Directors, including EpiCept Corporation, as Non-Executive Chairman, Targacept, Inc., Oragenics, Inc. and Palatin Technologies Inc. He earned his M.D. from New York University School of Medicine and a B.S. in Biochemistry, magna cum laude, from State University School of New York at Buffalo.

Dennis Langer, M.D., J.D.

Dennis H. Langer, M.D., J.D., has served as a member of our Board of Directors since February 2012. Dr. Langer brings over 25 years of experience in the pharmaceutical, biotechnology, and diagnostics industries in areas that include research & development, global and local marketing, and corporate development. Dr. Langer has served as a director of several public and private specialty pharmaceutical, biotechnology and diagnostic companies, and has been CEO and/or co-founder of several health care companies. From 2005 to 2010, Dr. Langer served as a Managing Partner of Phoenix IP Ventures, a private equity/venture capital firm specializing in life sciences. Previously, he was President, North America, of Dr. Reddy’s Laboratories Limited. From September 1994 until January 2004, Dr. Langer held several high-level positions at GlaxoSmithKline plc, and its predecessor, SmithKline Beecham including, most recently, as a Senior Vice President of Research & Development. Prior to SmithKline Beecham, Dr. Langer was President and CEO of Neose Technologies, Inc., and previously held research & development and marketing positions at Eli Lilly, Abbott Laboratories and GD Searle. At the beginning of his career, he was Chief Resident in Psychiatry at Yale University School of Medicine and held clinical fellowships at Harvard Medical School and the National Institutes of Health (NIH). Dr. Langer serves on the Board of Directors of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., and several private companies. Previously, Dr. Langer served as a Director of Myrexis, Inc., Auxilium Pharmaceutics, Inc., Sirna Therapeutics, Inc., Pharmacopeia, Inc., and Cytogen Corporation. Dr. Langer is a Clinical Professor in the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer received a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.

Martin Zeiger

Martin Zeiger has served as a member of our Board of Directors since May 2014. Since 2006, Mr. Zeiger has served as an Adjunct Partner at Signet Healthcare Partners, a New York City-based private equity fund focused on diversified healthcare investments. During his time at Signet Healthcare Partners, Mr. Zeiger sat on various Investment Portfolio Boards and has participated in advising on numerous investments. Mr. Zeiger, a licensed attorney, has over 40 years of experience in the pharmaceutical/allied health industry and has extensive legal and risk management experience. From 2000 until joining Signet Healthcare Partners, Mr. Zeiger served as a Senior Vice President at Barr Laboratories, Inc., a global specialty pharmaceutical company which was later acquired by Teva Pharmaceuticals. Prior to then, in 1987, Mr. Zeiger joined Rugby Laboratories, a privately held generic drug company, as its Executive Vice President and General Counsel until its acquisition by Marion Merrill Dow, Inc., in 1993. He continued as a Vice President for Marion Merrill Dow and its successor company, Hoechst Marion Roussel, Inc., until joining Barr Laboratories in 2000. Prior to joining Marion Merrill Dow, Mr. Zeiger served as Chief Legal Officer and conducted business development for Revco D.S. Inc., a drug store chain which was later acquired by CVS; and Jack Eckerd Corp., which was eventually sold to CVS and Rite Aid. Mr. Zeiger serves on the Board of Directors of BioPro Pharmaceutical, a biotechnology company; and SciDose LLC, a pharmaceutical company that develops and improves upon existing formulas of oncology and hospital injectable products. He has also served on the Board of Directors of Accu-Break Pharmaceuticals and Vasomedical, Inc. Mr. Zeiger earned his J.D. from St. John’s University School of Law and is admitted to practice in the State of New York.

Frederick Sancilio, M.S., Ph.D.

Frederick D. Sancilio, M.S., Ph.D., is our founder and has served as our Chairman, President and Chief Executive Officer since November 2006. Dr. Sancilio has over 40 years of experience in the pharmaceutical research, development, manufacturing and distribution industries. Prior to founding the Company, Dr. Sancilio founded three successful pharmaceutical companies, one of which includes aaiPharma Inc., a contract research organization. Dr. Sancilio is an experienced pharmaceutical executive, development scientist and accomplished entrepreneur. He has published over 20 articles in peer reviewed scientific journals, holds 14 domestic and international patents and has presented to scientists in conferences around the world. Over the course of his career, he has contributed to the development of over 1,000 drugs marketed in the United States, Europe and Asia. Dr. Sancilio earned a Ph.D. in Physical and Analytical Chemistry and an M.S. from Rutgers University.

Patrick Gray

Patrick Gray has served as a member of our Board of Directors since 2012. Mr. Gray brings extensive experience in accounting and financial reporting to our Board, having spent over 37 years with PricewaterhouseCoopers LLP (PwC) until his retirement in 2009. He is a Certified Public Accountant who spent 25 years as an Audit Partner serving clients ranging from Fortune 500 companies and multi-national companies to rapid-growth companies pursuing an initial public offering (IPO). At the time of his retirement, he served as the lead partner for the PwC U.S. firm Corporate Governance Group. Prior to that time, he held various other leadership positions with the firm, including leadership of the PwC U.S. High Technology Group. Mr. Gray earned a B.S. from The Wharton School of Business at the University of Pennsylvania and is a Certified Public Accountant.

Edward Mascioli, M.D.

Edward Mascioli, M.D., has served as a member of our Board of Directors since January 2016. Dr. Mascioli is an accomplished healthcare executive, entrepreneur and investor. He also has broad expertise in healthcare/life science venture capital, having led several equity and debt financings. Dr. Mascioli has held leadership roles in both large pharmaceutical and small biotechnology companies. Since May 2014, he has been a Venture Partner of SV Life Sciences Advisers, LLC, as a member of its biopharmaceutical investment team. Prior to this, he served as the Chief Executive Officer of Affinium Pharmaceuticals, Inc., from January 2013 to April 2014, leading its sale to Debiopharm International. During 2012, Dr. Mascioli consulted to various biopharmaceutical companies working in the rare disease therapeutic area. From 2010 to February 2012, Dr. Mascioli served as Vice President at Pfizer, Inc. and established and led its Rare Diseases Unit. In 2008, Dr. Mascioli founded Dapis Capital, LLC and served as its Managing Director through 2010. Dr. Mascioli also served as Chief Medical Officer at Peptimmune, Inc. Dr. Mascioli was a Venture Partner and Executive Partner of MPM Capital from 2001 through 2008. Prior to joining MPM, he was an Executive Medical Director at Parexel, a leading international clinical research organization, where his clients ranged from small biotechnology to large multinational pharmaceutical companies.  His entrepreneurial experience includes founding, funding, and operating a successful outpatient medical services company for two years. Prior to his entrepreneurial experience, Dr. Mascioli was on the faculty of Harvard Medical School as an Assistant Professor of Medicine and on the staff of the Deaconess Hospital (now Beth Israel Deaconess Hospital) in Boston. Dr. Mascioli holds an M.S. in Nutritional Biochemistry and Metabolism from the Massachusetts Institute of Technology, an M.D. from the University of Massachusetts Medical School, and a B.A. in Biology, cum laude, from Brandeis University.

Luke Beshar

Luke Beshar has served as a member of our board of directors since January 2016. Mr. Beshar brings over 35 years of experience as a finance executive with extensive experience in the pharmaceutical industry. From November 2007 to February 2015, Mr. Beshar served as Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of therapies targeting rare diseases. Prior to NPS Pharmaceuticals, from 2002 to 2007, Mr. Beshar served as Executive Vice President and Chief Financial Officer and later as Executive Vice President, Strategy & Corporate Development of Cambrex Corporation, a global life sciences company offering cGMP manufacturing services for biopharmaceutical and cell therapies as well as bioresearch and drug discovery tools. Prior to Cambrex, Mr. Beshar served as a senior executive and Chief Financial Officer for various public and private companies in various industries, including Dendrite International, a worldwide leader in sales force effectiveness and customer relationship management software, Expanets, Inc., a provider of advanced voice and data communications solutions, PNY Technologies, Inc., a computer memory manufacturer, WSR Corporation, an automotive aftermarket retailer and The Genlyte Group, Inc., a manufacturer of lighting fixtures. Mr. Beshar began his career with Arthur Andersen & Co. and is a certified public accountant. He obtained his bachelor’s degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia.  Mr. Beshar currently serves as a Director and Chair of the Audit Committee of Trillium Therapeutics Inc., a public immune-oncology company developing therapies for the treatment of cancer, a Director, Chair of the Audit Committee, and member of the Compensation Committee of REGENXBIO Inc., a leading gene therapy development public company, and a Director of EnteraBio a private biopharmaceutical company focused on the development of orally delivered large molecule therapeutics.

Google+   Likedin